Position in ARGX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$2,734,138
+$879,303 QoQ
Shares Held
2,947
+16.0% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#179
of 504 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in ARGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GREAT VALLEY ADVISOR GROUP, INC. holds $5,771,539 across 13 Biotechnology names. ARGX ranks #1 (47.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
This page
|
2,947 | $2,734,138 | |
| 2 | CELC |
Celcuity Inc.
|
5,591 | $584,930 | |
| 3 | INCY |
Incyte Corp
|
5,040 | $571,334 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
874 | $434,142 | |
| 5 | SMMT |
Summit Therapeutics Inc.
|
25,840 | $376,488 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,080 | $260,247 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
379 | $236,321 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
2,700 | $201,096 |
All Filings in ARGX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,734,138 | 2,947 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $1,854,835 | 2,540 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,513,710 | 1,800 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,281,879 | 1,738 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $600,829 | 1,090 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $336,179 | 568 | Shares | Sole | 2025-05-08 | |
| No filing history on record for this holder in this stock. | ||||||